Curiously, these genes were affected by widespread of loss-of-function mutations in tumour suppressors (TP53, ARID1A, SMAD4) whereas no obvious oncogenic mutations linked to EAC progression were identified. The gene discussed is SMAD4; the disease is neoplasm.